Phosphorylated Tau 231 (P Tau 231) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Phosphorylated Tau 231 (P Tau 231) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Phosphorylated Tau 231 (p-tau 231) is a highly sensitive cerebrospinal fluid (CSF) and blood-based biomarker for detecting early tau pathology in Alzheimer's disease and other tauopathies. The 231 refers to the threonine phosphorylation site at position 231 on the tau protein.
Tau protein is a microtubule-associated protein that stabilizes neuronal microtubules. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, leading to its aggregation into neurofibrillary tangles (NFTs). The phosphorylation at threonine 231 (T231) occurs early in the disease process, making p-tau 231 one of the earliest detectable markers of tau pathology[1].
The T231 phosphorylation site is particularly significant because:
p-tau 231 demonstrates superior sensitivity for detecting early AD pathology compared to p-tau 181, particularly in the preclinical and mild cognitive impairment (MCI) stages[2]. Studies show that p-tau 231 levels begin to rise approximately 10-15 years before clinical symptoms appear.
The early detection capability of p-tau 231 makes it valuable for:
| Disease Stage | p-tau 231 Level | Clinical Correlation |
|---|---|---|
| Preclinical | Moderately elevated | Amyloid positivity, no symptoms |
| MCI due to AD | Significantly elevated | Memory complaints |
| Mild AD | Highly elevated | Mild cognitive impairment |
| Moderate AD | Very high | Moderate cognitive decline |
| Severe AD | Highest levels | Severe dementia |
p-tau 231 helps differentiate Alzheimer's disease from other dementias[3]:
The gold standard for p-tau 231 measurement uses ELISA (Enzyme-Linked Immunosorbent Assay) kits from analytical companies like Fujirebio and Roche. CSF collection requires lumbar puncture, typically performed at the L3-L4 or L4-L5 vertebral level.
Key considerations for CSF collection:
Recent advances in ultrasensitive immunoassays (Simoa, Lumipulse) enable p-tau 231 detection in blood samples[4]. This represents a major breakthrough for:
Typical reference values (may vary by laboratory):
| Biomarker | Primary Use | Earliest Detection | Specificity |
|---|---|---|---|
| p-tau 231 | Early AD detection | Preclinical (10-15 years) | High |
| p-tau 181 | AD vs. other dementias | Preclinical (5-10 years) | Very High |
| p-tau 217 | Disease progression | Preclinical (15-20 years) | Very High |
| Total tau (t-tau) | Neuronal damage | Variable | Moderate |
p-tau 231 is increasingly used as an enrichment biomarker in clinical trials for anti-amyloid and anti-tau therapies. Patients with elevated p-tau 231 are more likely to have active tau pathology, making them ideal candidates for tau-targeting interventions[5].
Key trial applications:
Optimal biomarker panels often include:
p-tau 231 levels correlate with response to various therapeutic approaches:
Longitudinal p-tau 231 measurements can track disease modification:
Phosphorylated Tau 231 (p-tau 231) represents one of the earliest and most sensitive biomarkers for detecting tau pathology in Alzheimer's disease. Its ability to detect changes 10-15 years before clinical symptoms, combined with emerging blood-based testing, positions p-tau 231 as a crucial tool for early diagnosis, clinical trial enrichment, and therapeutic monitoring. The integration of p-tau 231 with other biomarkers (Aβ42/40, p-tau 181, NfL) enables comprehensive characterization of Alzheimer's disease pathology and progression.
Phosphorylated Tau 231 (P Tau 231) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Phosphorylated Tau 231 (P Tau 231) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.